Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track ABSI with free AI briefings, catalyst countdowns, and dilution alerts.

ABSI — Absci Corporation

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$20M Cash on Hand

5.7mo Cash Runway

29.7% Short Interest

🧪 Upcoming Trial Catalysts

2028-07-01 · Phase 1, Phase 2 — Recruiting — Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and

📊 Drug Pipeline

Drug	Indication	Phase	Status
ABS-201 IV Single Dose	Androgenetic Alopecia (AGA)	PHASE1	RECRUITING
ABS-201 SC Multiple Doses	Androgenetic Alopecia (AGA)	PHASE1	RECRUITING

💰 Cash Runway & Dilution Risk

ABSI holds $20M in cash and burns about $10.5M/quarter from operations, giving an estimated runway of 5.7 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ABSI free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-03-16	McClain Sean	Purchase	$0
2026-03-16	McClain Sean	Purchase	$0
2026-03-16	Bedrick Todd	Purchase	$0
2026-03-16	Bedrick Todd	Purchase	$0
2026-03-16	Jonasson Zachariah	Purchase	$0

Get the full ABSI picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ABSI and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z